Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2019, Article ID 2807926, 8 pages
https://doi.org/10.1155/2019/2807926
Research Article

Jian-Pi-Yi-Shen Decoction Relieves Renal Anemia in 5/6 Nephrectomized Rats: Production of Erythropoietin via Hypoxia Inducible Factor Signaling

1Shenzhen Key Laboratory of Hospital Chinese Medicine Preparation, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, China
2Department of Nephrology, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, China

Correspondence should be addressed to Jianping Chen; moc.621@pjcyl and Shunmin Li; moc.361@nimnuhsilyyz

Received 7 January 2019; Accepted 12 February 2019; Published 3 March 2019

Guest Editor: José Carlos Tavares Carvalho

Copyright © 2019 Jianping Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Fishbane and B. Spinowitz, “Update on anemia in ESRD and earlier stages of CKD: core curriculum 2018,” American Journal of Kidney Diseases, vol. 71, no. 3, pp. 423–435, 2018. View at Publisher · View at Google Scholar · View at Scopus
  2. J. L. Babitt and H. Y. Lin, “Mechanisms of anemia in CKD,” Journal of the American Society of Nephrology, vol. 23, no. 10, pp. 1631–1634, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Fishbane, B. Singh, S. Kumbhat, W. A. Wisemandle, and N. E. Martin, “Intravenous epoetin Alfa-epbx versus epoetin alfa for treatment of anemia in end-stage kidney disease,” Clinical Journal of the American Society of Nephrology, vol. 13, no. 8, pp. 1204–1214, 2018. View at Publisher · View at Google Scholar · View at Scopus
  4. S. C. Palmer, V. Saglimbene, D. Mavridis et al., “Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis,” The Cochrane Database of Systematic Reviews, no. 12, p. D10590, 2014. View at Google Scholar
  5. G. M. Chertow, J. Liu, K. L. Monda et al., “Epoetin alfa and outcomes in dialysis amid regulatory and payment reform,” Journal of the American Society of Nephrology, vol. 27, no. 10, pp. 3129–3138, 2016. View at Publisher · View at Google Scholar · View at Scopus
  6. F. Dou, H. Miao, J.-W. Wang et al., “An integrated lipidomics and phenotype study reveals protective effect and biochemical mechanism of traditionally used Alisma orientale Juzepzuk in chronic kidney disease,” Frontiers in Pharmacology, vol. 9, p. 53, 2018. View at Google Scholar · View at Scopus
  7. X. Wang, S. Yu, Q. Jia et al., “NiaoDuQing granules relieve chronic kidney disease symptoms by decreasing renal fibrosis and anemia,” Oncotarget , vol. 8, no. 34, pp. 55920–55937, 2017. View at Google Scholar · View at Scopus
  8. K. Wang, J. Wu, J. Xu et al., “Correction of anemia in chronic kidney disease with angelica sinensis polysaccharide via restoring EPO production and improving iron availability,” Frontiers in Pharmacology, vol. 9, p. 803, 2018. View at Publisher · View at Google Scholar
  9. D. Wang, J. Chen, X. Liu et al., “A Chinese herbal formula, Jian-Pi-Yi-Shen decoction, improves muscle atrophy via regulating mitochondrial quality control process in 5/6 nephrectomised rats,” Scientific Reports, vol. 7, no. 1, p. 9253, 2017. View at Publisher · View at Google Scholar
  10. J. Lu, X. Liu, Y. Liao, D. Wang, J. Chen, and S. Li, “Jian-Pi-Yi-Shen formula regulates inflammatory cytokines production in 5/6 nephrectomized rats via suppression of NF-kappaB activation,” Evidence-Based Complementary and Alternative Medicine, vol. 2018, Article ID 7203547, 7 pages, 2018. View at Publisher · View at Google Scholar
  11. X. Liu, J. Chen, X. Liu et al., “Jian-Pi-Yi-Shen Formula ameliorates chronic kidney disease: involvement of mitochondrial quality control network,” BMC Complementary and Alternative Medicine, vol. 18, no. 1, p. 340, 2018. View at Publisher · View at Google Scholar
  12. J. Chen, A. Gong, X. Liu et al., “A Chinese herbal decoction, Jian-Pi-Yi-Shen, regulates the expressions of erythropoietin and pro-inflammatory cytokines in cultured cells,” BMC Complementary and Alternative Medicine, vol. 18, no. 1, p. 119, 2018. View at Google Scholar
  13. X. Liu, S. Huang, F. Wang et al., “Huangqi-danshen decoction ameliorates adenine-induced chronic kidney disease by modulating mitochondrial dynamics,” Evidence-Based Complementary and Alternative Medicine, vol. 2019, Article ID 9574045, 8 pages, 2019. View at Publisher · View at Google Scholar
  14. J. M. Kaplan, N. Sharma, and S. Dikdan, “Hypoxia-inducible factor and its role in the management of anemia in chronic kidney disease,” International Journal of Molecular Sciences, vol. 19, no. 2, p. E389, 2018. View at Google Scholar · View at Scopus
  15. C. M. Wyatt and T. B. Drüeke, “HIF stabilization by prolyl hydroxylase inhibitors for the treatment of anemia in chronic kidney disease,” Kidney International, vol. 90, no. 5, pp. 923–925, 2016. View at Publisher · View at Google Scholar · View at Scopus
  16. X. Liu, J. Wu, J. Wang et al., “Possible role of mitochondrial injury in Caulis Aristolochia manshuriensis-induced chronic aristolochic acid nephropathy,” Drug and Chemical Toxicology, vol. 40, no. 1, pp. 115–124, 2017. View at Publisher · View at Google Scholar · View at Scopus
  17. F. Locatelli, S. Fishbane, G. A. Block, and I. C. MacDougall, “Targeting hypoxia-inducible factors for the treatment of anemia in chronic kidney disease patients,” American Journal of Nephrology, vol. 45, no. 3, pp. 187–199, 2017. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Li, R. N. Foley, and A. J. Collins, “Anemia and cardiovascular disease, hospitalization, end stage renal disease, and death in older patients with chronic kidney disease,” International Urology and Nephrology, vol. 37, no. 2, pp. 395–402, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Sugahara, T. Tanaka, and M. Nangaku, “Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease,” Kidney International, vol. 92, no. 2, pp. 306–312, 2017. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Rahman, D. Yamazaki, A. Sufiun et al., “A novel approach to adenine-induced chronic kidney disease associated anemia in rodents,” PLoS ONE, vol. 13, no. 2, Article ID e192531, 2018. View at Publisher · View at Google Scholar
  21. X. Yu, Y. Fang, H. Liu et al., “The balance of beneficial and deleterious effects of hypoxia-inducible factor activation by prolyl hydroxylase inhibitor in rat remnant kidney depends on the timing of administration,” Nephrology Dialysis Transplantation , vol. 27, no. 8, pp. 3110–3119, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Morgera, P. Heering, T. Szentandrasi, C. Niederau, and B. Grabensee, “Erythropoietin in patients with acute renal failure and continuous veno- venous haemofiltration,” International Urology and Nephrology, vol. 29, no. 2, pp. 245–250, 1997. View at Publisher · View at Google Scholar · View at Scopus
  23. A. A. Joharapurkar, V. B. Pandya, V. J. Patel, R. C. Desai, and M. R. Jain, “Prolyl hydroxylase inhibitors: a breakthrough in the therapy of anemia associated with chronic diseases,” Journal of Medicinal Chemistry, vol. 61, no. 16, pp. 6964–6982, 2018. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Xu, J. S. Nagati, J. Xie et al., “An acetate switch regulates stress erythropoiesis,” Nature Medicine, vol. 20, no. 9, pp. 1018–1026, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Serocki, S. Bartoszewska, A. Janaszak-Jasiecka, R. J. Ochocka, J. F. Collawn, and R. Bartoszewski, “miRNAs regulate the HIF switch during hypoxia: a novel therapeutic target,” Angiogenesis, vol. 21, no. 2, pp. 183–202, 2018. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Flisinski, E. Wisniewska-Chudy, A. Brymora, A. Stefanska, P. Strozecki, and J. Manitius, “Chronic kidney disease leads to hypoxia inducible factor-1alpha to hypoxia inducible factor-2alpha switch in the gastrocnemius muscle,” Journal of Physiology and Pharmacology, vol. 68, no. 3, pp. 419–425, 2017. View at Google Scholar · View at Scopus
  27. M. Heikkilä, A. Pasanen, K. I. Kivirikko, and J. Myllyharju, “Roles of the human hypoxia-inducible factor (HIF)-3α variants in the hypoxia response,” Cellular and Molecular Life Sciences, vol. 68, no. 23, pp. 3885–3901, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. C. E. Anderson, L. L. Hamm, G. Batuman et al., “The association of angiogenic factors and chronic kidney disease,” BMC Nephrology, vol. 19, no. 1, 2018. View at Publisher · View at Google Scholar
  29. S. R. Keithi-Reddy, F. Addabbo, T. V. Patel, B. V. Mittal, M. S. Goligorsky, and A. K. Singh, “Association of anemia and erythropoiesis stimulating agents with inflammatory biomarkers in chronic kidney disease,” Kidney International, vol. 74, no. 6, pp. 782–790, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. P. G. Fraenkel, “Anemia of Inflammation: A Review,” Medical Clinics of North America, vol. 101, no. 2, pp. 285–296, 2017. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Zaritsky, B. Young, H.-J. Wang et al., “Hepcidin—a potential novel biomarker for iron status in chronic kidney disease,” Clinical Journal of the American Society of Nephrology, vol. 4, no. 6, pp. 1051–1056, 2009. View at Publisher · View at Google Scholar · View at Scopus